NDLI: A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in Japan

Content Provider	PubMed Central
Author	Tanimoto, Tetsuya
Copyright Year	2015
Abstract	The universal health care system in Japan is facing a historical turning point as a result of the increasing fiscal burden, rapidly aging society, and a decreasing population. To understand the challenges and opportunities in the Japanese pharmaceutical market, which occupies one tenth of the global share, this review highlights several issues related to the benefit-risk assessment that is unique to the modern Japanese society: 1) regulatory system for new drug development; 2) health hazards related to pharmaceuticals (“Yakugai” in Japanese); 3) drug lag; 4) problems and controversies in the vaccination policy; and 5) clinical study misconduct. The regulatory process places a significant importance on Japanese data collection regardless of data accumulation from other countries. Because Yakugai has repeatedly caused tragedies and social disputes historically, the regulatory judgments generally tend to be more prudential when safety concerns are raised for new and emerging pharmaceuticals. Such a regulatory system has caused more than several years of approval delays compared to delays in other countries. The problem of drug lag still lingers on despite several regulatory system revisions, while the solution is incompatible with the elimination of Yakugai because the lag potentially reduces the risk of unpredictable adverse events. The Japanese vaccination policy has also received a lot of criticism, and needs improvements so that the decision-making process can be more transparent and scientifically based. Additionally, repeated clinical study misconduct damaged the reputation of Japanese clinical studies with unnecessary defrayment in health insurance; therefore, the medical community must change its inappropriate relationship with the industry. The problems surrounding pharmaceuticals are related to centralized, strict drug pricing control under the universal health coverage. Although the current government attempts to facilitate innovative research and development of novel therapeutics in Japan, further reforms should be explored for patients who need new and emerging pharmaceuticals.
Related Links	http://dx.doi.org/10.2147/dddt.s62636
Ending Page	1888
Page Count	12
Starting Page	1877
File Format	PDF
ISSN	11778881
e-ISSN	11778881
Journal	Drug Design, Development and Therapy
Volume Number	9
Language	English
Publisher	Dove Medical Press
Publisher Date	2015-03-01
Access Restriction	Open
Rights Holder	Dove Medical Press
Subject Keyword	Pharmacology Drug Discovery Pharmaceutical Science Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Drug Discovery Pharmacology Pharmaceutical Science

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in Japan

A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in Japan

Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran

Wound healing: a new perspective on glucosylated tetrahydrocurcumin

A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in Japan

New and emerging treatments for symptomatic tardive dyskinesia

Current and emerging pharmacological treatments for sarcoidosis: a review

Ceftobiprole for the treatment of pneumonia: a European perspective

Antiviral therapy: a perspective

A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in Japan

Similar Documents

A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in Japan

A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in Japan

Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran

Wound healing: a new perspective on glucosylated tetrahydrocurcumin

A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in Japan

New and emerging treatments for symptomatic tardive dyskinesia

Current and emerging pharmacological treatments for sarcoidosis: a review

Ceftobiprole for the treatment of pneumonia: a European perspective

Antiviral therapy: a perspective

A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in Japan